10/13 Taiwan BIO Weekly
2025-10-13 |
| Taiwan BIO Weekly |
| National Infectious Disease Bank to be completed next year, NHRI says 11 October, 2025 The National Infectious Disease Bank is expected to be completed next year, facilitating Taiwan's research and international cooperation on epidemic prevention, National Health Research Institutes (NHRI) president Sytwu Huey-kang said yesterday. The NHRI has been constructing the facility to support the development of epidemic-prevention technologies, domestically produced vaccines, diagnostic reagents and new medicines to combat infectious diseases, Sytwu said. More... |
| TaiGen Biotechnology signs new drug licensing agreement, officially enters Vietnam market 2 October, 2025 TaiGen (TW: 4157) announced that its subsidiary, TaiGen Biotechnology, has signed a licensing agreement with Vietnamese pharmaceutical companies Fideschem and Newsun Pharmaceutical JSC for its new antibiotic Taigexyn in Vietnam, further expanding its Southeast Asian presence after Malaysia and Singapore. The agreement grants Fideschem and Newsun joint rights to develop and commercialize Taigexyn in both oral capsule and intravenous formulations in Vietnam, including handling local regulatory approvals and market sales, with a term of 20 years from the effective date. More... (in Chinese) |
| Diamond Biofund increases capital investment in its subsidiary startup 25 September, 2025 Diamond Biofund (TW: 6901) announced that it will inject an additional NT$450 million into its subsidiary startup, ImmunAdd, to accelerate the company's chemical total synthesis technology development and address the high cost of natural saponin adjuvants. Diamond Biofund led ImmunAdd's first fundraising round in 2023 and remains its largest institutional shareholder. After two years of development, ImmunAdd has completed the early validation of its synthetic saponin adjuvant, which is about to enter Phase I clinical trials. Once safety and efficacy data in humans are obtained, the company aims to accelerate licensing and collaboration with major international vaccine manufacturers. More... (in Chinese) |
| Anxo Pharmaceutical signs licensing deal in the Middle East 1 October, 2025 Anxo Pharmaceutical (TW: 6677) announced that its co-developed P4 generic drug for pulmonary fibrosis, NTN, has secured a Middle East licensing and distribution agreement and had its ANDA accepted for FDA review. NTN, a technically complex semi-solid suspension softgel, was formulated and developed by Anxo, with its domestic partner handling manufacturing. Both companies share development costs and will jointly receive sales revenue once the product is launched globally. More... (in Chinese) |
| TAHO Pharmaceuticals submits FDA NDA application for oral soluble film antithrombotic drug TAH3311 1 October, 2025 OTC biotech company TAHO Pharmaceuticals (TW: 6467) announced that it submitted a New Drug Application (NDA) to the US FDA on September 30 for its globally first TAH3311 oral soluble film antithrombotic drug, aiming for US market approval by the second half of next year to capture a US$26.1 billion annual market opportunity. More... (in Chinese) |
| Protect Animal Health partners with Graphen Drugomics to target global pet joint care market 1 October, 2025 Protect Animal Health (TW: 7850) announced that it has formed a strategic alliance with US AI drug development company Graphen Drugomics, jointly accelerating the development and global commercialization of a canine osteoarthritis drug to capture the nearly US$3 billion global pet joint care market. Protect Animal Health stated that the collaboration leverages Graphen's expertise in front-end AI innovation, while Protect acts as the international commercialization operator. More... (in Chinese) |
| tcmc Highlights CAR-T Innovation at BioJapan 2025, Catalyzing Taiwan-Japan Cancer Cell Therapy Partnerships Press release 1 October, 2025 Taiwan Cell Manufacturing Company (tcmc), a state-of-the-art CDMO specializing in cell and gene therapy (CGT) manufacturing, is participating in BioJapan 2025 - Asia's premier biotechnology exhibition -- taking place October 8-10 in Yokohama, Japan. At this influential event, tcmc will showcase its world-class CDMO services, foster strategic collaborations, and champion innovation in CAR-T cell therapy and regenerative medicine across Asia and beyond. More... |
| Locus Cell signs smart manufacturing deal with Australia’s Cambium Bio 30 September, 2025 Taiwan’s regenerative medicine CDMO Locus Cell (TW: 6891) announced it has signed an MOU with Australia's Cambium Bio (CMB.AX) to provide CDMO services for Elate Ocular, the world's first regenerative biologic for dry eye disease, with production capacity to be supported by its Zhubei plant set for completion in 2026. The company said the collaboration highlights global recognition of Locus Cell's smart manufacturing and advances its goal of being based in Taiwan, serving global clients. Cambium, formed in 2024 through the merger of Taiwan-backed Cambium Medical Technology and Australia's Regeneus, develops therapies based on patented human platelet lysate (hPL) technology, with a pipeline spanning dry eye disease, osteoarthritis, and other tissue repair indications. More... (in Chinese) |
| Genomics and Illumina partner to launch genomic services in Asia-Pacific 30 September, 2025 Genomics (TW: 4195) announced that it has formed a strategic partnership with global industry leader Illumina to jointly promote the adoption of genomic sequencing and multi-omics technologies across the Asia-Pacific region, accelerating diversified industry development and tapping into the vast potential of whole-genome sequencing (WGS). Following the signing of an MOU late last year, both companies have already begun advancing related technologies and services, and recently co-hosted an academic symposium on multi-omics innovation services. More... (in Chinese) |
| Taiwan Bio and Unicocell accelerate push into regenerative medicine 29 September, 2025 Taiwan's regenerative medicine industry is gradually maturing. In addition to investing in regenerative medicine technologies and cell therapy drug development, several companies; including MetaTech, parent of Locus Cell (TW: 6891), Taiwan Bio Therapeutics (TW: 6892), Unicocell Biomed, and Meribank Biotech, have had their PIC/S GMP pilot plants certified by the Ministry of Health and Welfare. Beyond developing original regenerative medicine products, these companies are also actively pursuing overseas CDMO orders. More... (in Chinese) |
| Locus Cell's Zhubei Smart GMP Facility Secures First International Phase III CDMO Manufacturing MOU with Cambium Bio Press release 29 September, 2025 Locus Cell (TW: 6891), a leading regenerative medicine CDMO in Taiwan, announced it has signed a Memorandum of Understanding (MOU) with Australia-based Cambium Bio (ASX: CMB). Under the agreement, Cambium will entrust Locus Cell with the contract development and manufacturing (CDMO) of Elate Ocular -related. Elate Ocular, a Phase III dry eye disease therapy currently under clinical trials in Taiwan, the US, and Australia. The technology originates from Cambium's parent company, Zheng Yang Biomedical Technology Co., Ltd. More... |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Tel: +886 2 27836028 Fax: +886 2 27836027 Email: biotaiwan@gmail.com BIO Asia-Taiwan 2026 (15-19 July, 2026) ========================================= Taiwan Bio Industry Organization (Taiwan BIO) Room C229, 2F, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |